Puma biotechnology press release outlet
Puma biotechnology press release outlet
Puma biotechnology press release outlet
Puma biotechnology press release outlet
Puma biotechnology press release outlet
Puma biotechnology press release outlet

Puma biotechnology press release outlet

Puma biotechnology press release outlet, Puma Biotechnology Inc. Puma Biotechnology Presents Results from the Phase II SUMMIT Trial of Neratinib for ERBB2 HER2 Mutant HER2 Non Amplified Metastatic Breast Cancer at the 2019 San Antonio Breast... outlet

$54.00

SKU: 7602402

Colour
  • Puma Biotechnology Inc CEO Alan Auerbach Sells 41 396 Shares
  • Puma Biotech starts phase II trial for lung cancer therapy By Investing
  • Puma biotechnology press hot sale release
  • Puma Biotechnology announces presentation of findings from a phase II study of alisertib in endocrine resistant metastatic breast cancer Express Pharma
Out of stock
Personalised:
: ( x )
Personalisation:
Edit
Remove Personalisation
Frasers Plus

Buy now.

Pay later.

Earn rewards

Representative APR: 29.9% (variable)

Credit subject to status. Terms apply.

Missed payments may affect your credit score

FrasersPlus